Generic Name and Formulations:
Mercaptopurine (6-MP) 20mg/mL; oral susp; contains fruit extract, aspartame.
Rare Disease Therapeutics, Inc.
Indications for PURIXAN:
Maintenance therapy of acute lymphoblastic leukemia as part of a combination regimen.
Adults and Children:
Shake bottle vigorously for at least 30 secs. Initially 1.5–2.5mg/kg (50–75mg/m2) per day as a single dose. Monitor subsequent doses to maintain desirable ANC level and adjust for excessive hematological toxicity. Thiopurine-S-methyltransferase (TPMT) and/or nucleotide diphosphatase (NUDT15)-deficient: if homozygous, may require ≤10% of standard dose; if heterozygous, some may require dose reduction based on toxicities. Renal or hepatic impairment: use lower starting doses; monitor for toxicity. See full labeling.
Myelosuppression; monitor CBCs and adjust dose for severe neutropenia and thrombocytopenia. Consider testing for TPMT and NUDT15 deficiency in patients who experience severe bone marrow toxicities or repeated myelosuppression. Monitor serum transaminase, alkaline phosphatase, and bilirubin levels at weekly intervals when starting therapy, then monthly thereafter; interrupt treatment if evidence of hepatotoxicity occurs. Concomitant other hepatotoxic drugs or with pre-existing liver disease; monitor LFTs more frequently. Immunosuppression. Increased risk of lymphoproliferative disorders and other malignancies (eg, skin cancers, sarcomas, uterine cervical cancer). Concomitant multiple immunosuppressants increase risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders. Monitor and treat for EBV or cytomegalovirus; discontinue if macrophage activation syndrome occurs, or is suspected. Renal or hepatic impairment. Elderly. Embryo-fetal toxicity. Pregnancy (esp. 1st trimester), nursing mothers: not recommended.
Avoid concomitant allopurinol. Increased risk of bone marrow suppression with allopurinol, aminosalicylate derivatives (eg, olsalazine, mesalamine, sulfasalazine), trimethoprim-sulfamethoxazole. Possibly decreased effectiveness with concomitant warfarin; monitor PT or INR; may need warfarin dose adjustments. Concomitant live virus vaccines: may get suboptimal response and risk of infection.
Myelosuppression, nausea, vomiting, anorexia, diarrhea, malaise, rash, urticaria, hyperuricemia, oral lesions, elevated transaminases, hyperbilirubinemia, hyperpigmentation, pancreatitis; hepatotoxicity.
Susp—100mL (w. oral syringes)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Rapid Cycling in Bipolar Disorder: Overview and Expert Perspectives
- Posttraumatic Stress Disorder Associated With Reduced Brain Volume
- First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide
- ADHD Medications Compared for Efficacy, Tolerability in Children and Adults
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Healthcare Community Should Favor More Restrictive Alcohol Policies
- How to Respond to a Patient's Request for Prayer: A Clinician's Dilemma
- Major Barriers to Useful Risk Prediction Must Be Overcome to Reach the Full Potential of Big Data
- ACA Coverage Gains Include Workers Without Insurance
- Steps Provided for Discharging Patients From Practice